Furthermore, patients with NSCLC treated with PD-1/PD-L1/CTLA-4 inhibitors and having ARID1A, ARID1B, or ARID2 mutations of the SWI/SNF complex showed better outcomes in comparison to those without such mutations. Here, ARID1B is linked to non-small cell lung carcinoma.